acetylsalicylic acid intravenous (BAY 81-8781) / Bayer - LARVOL DELTA

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) (PRNewswire) - P3 | N=27,395 | COMPASS (NCT01776424) | P=N/A | N=5,798 | XATOA (NCT03746275) | Sponsor: Bayer | "Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published...The findings showed that XARELTO® 2.5 mg twice daily plus aspirin 75 mg to 100 mg once daily was associated with a primary outcome event rate (CV death, stroke or MI) of 2.35 (95% CI 2.11-2.61 per 100 patient years; n=353), which was similar to the rate observed during the randomized treatment phase (2.18 [95% CI 1.97-2.41] per 100 patient years; n=379)....The full analysis set consisted of 5,532 patients with CAD and/or PAD who received at least one dose of DPI with XARELTO® 2.5 mg and aspirin. Of the patients in the full analysis set, 4,022 (72.7%) had CAD, 3,258 (58.9%) had PAD, and 1,748 (31.6%) had both CAD and PAD."

Clinical data • P3 data • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Peripheral Arterial Disease